Заключение

Эти результаты впервые показали, что ws-lynx1 может связываться с некоторыми подтипами нАХР по конкурентному механизму (в классическом центре связывания агонистов и антагонистов, хорошо охарактеризованном соответствующими кристаллическими структурами комплексов с АХБ), а также по неконкурентному - за пределами этого центра.

Таким образом, ведущиеся в настоящее время исследования открывают новые перспективы для использования высокоаффинных и селективных лигандов никотиновых рецепторов в качестве лекарственных препаратов.

Литература

Akaike A., Takada-Takatori Y., Kume T., Izumi Y. Mechanisms of neuroprotective effects of nicotine and acetylcholinesterase inhibitors: role of alpha4 and alpha7 receptors in neuroprotection // J. Mol. Neurosci. 2010. Vol. 40. P. 211-216.

Alkondon M., Rocha E.S., Maelicke A., Albuquerque E.X. Diversity of nicotinic acetylcholine receptors in rat brain. V alpha-Bungarotoxin-sensitive nicotinic receptors in olfactory bulb neurons and presynaptic modulation of glutamate release //J. Pharmacol. Exp.Ther. 1996. Vol. 278. P. 1460-1471.

Azam L., Winzer-Serhan U.H., Chen Y., Leslie F.M. Expression of neuronal nicotinic acetylcholine receptor subunit mRNAs within midbrain dopamine neurons // J. Comp. Neurol. 2002. Vol. 444. P. 260-274.

Changeux J.P. Nicotine addiction and nicotinic receptors: lessons from genetically modified mice // Nat. Rev. Neurosci. 2010. Vol. 11. P. 389-401.

Cohen J.B., WeberM., HuchetM., Changeux J.P. Purification from Torpedo marmorata electric tissue of membrane fragments particularly rich in cholinergic receptor protein // FEBS Lett. 1972. Vol. 26. P. 43-47.

Conti-Fine B.M., Navaneetham D., Lei S., Maus A.D. Neuronal nicotinic receptors in non-neuronal cells: new mediators of tobacco toxicity? // Eur.

Court J., Martin-Ruiz C., PiggottM., Spurden D., Griffiths M., Perry E. Nicotinic receptor abnormalities in Alzheimer’s disease // BHiol. Psychiatry. 2001. Vol. 49. P. 175-84.

DAndreaM.R., LeeD.H., WangH.Y., NageleR.G. Targeting intracellular АР42 for Alzheimer’s disease drug discovery // Drug Development Res. 2002. Vol. 56. P 194-200.

Dineley K.T. Beta-amyloid peptide - nicotinic acetylcholine receptor interaction: the two faces of health and disease // Front Biosci. 2007. Vol. 12. P. 5030-5038.

Dineley K.T., WestermanM., BuiD. et al. P-Amyloid activates the mitogen-activated protein kinase cascade via hippocampal a7 nicotinic acetylcholine receptors: in vitro and in vivo mechanisms related to Alzheimer’s disease // J. Neurosci. 2001. Vol. 21, P. 4125-4133.

EldefrawiM.E., EldefrawiA.T. Purification and molecular properties of the acetylcholine receptor from Torpedo electroplax // Arch. Biochem. Biophys. 1973. Vol. 159. P. 362-373.

Gotti C., ClementiF. Neuronal nicotinic receptors: from structure to pathology // Prog. Neurobiol. 2004. Vol. 74. P. 363-396.

Grady S.R., Salminen O., J. McIntosh M., Marks M.J., Collins A.C. Mouse striatal dopamine nerve terminals express a4a5p2 and two stoichiometric forms of a4p2*-nicotinic acetylcholine receptors // J. Mol. Neurosci. 2010. Vol. 40. P 91-95.

Han T.S., Teichert R.W., Olivera B.M., Bulaj G. Conus venoms - a rich source of peptide-based therapeutics // Curr Pharm. Des. 2008. Vol. 14. P 2462-2479.

Henderson B.J., Carper D.J., Gonzalez-Cestari T.F. et al. Structure-activity relationship studies of sulfonyl- piperazine analogues as novel negative allosteric modulators of human neuronal nicotinic receptors // J. Med. Chem. Dec. 2011. Vol. 54. P 8681-92.

Hernandez C.M., Dineley K.T. a7 nicotinic acetylcholine receptors in Alzheimer's disease: neuroprotective, neurotrophic or both? // Curr. Drug. Targets. 2012. Vol. 13. P. 613-622.

Hone A.J., Whiteaker P., Mohn J.L., Jacob M.H., McIntosh J.M.

Hucho F., Weise C. Ligand-Gated Ion Channels // Angew. Chem. Int. Ed. 2001. Vol. 40. P. 3100-3116.

Janson A.M., Fuxe K., Goldstein M. Differential effects of acute and chronic nicotine treatment on MPTP-(1- methyl-4-phenyl-1,2,3,6-tetrahydropyridine) induced degeneration of nigrostriatal dopamine neurons in the black mouse // Clin. Investig. 1992. Vol. 70. P 232-238.

KasheverovI.E., ZhmakM.N., KhruschovA.Y., Tsetlin V.I. Design of new a-conotoxins: from computer modeling to synthesis of potent cholinergic compounds // Mar. Drugs. 2011. Vol. 9. P 1698-1714.

KlinkR., de Kerchove d’Exaerde A., Zoli M., Changeux J.P. Molecular and physiological diversity of nicotinic acetylcholine receptors in the midbrain dopaminergic nuclei // J. Neurosci. 2001. Vol. 21. P 1452-63.

Kukhtina V., Kottwitz D., Strauss H., Heise B., Chebotareva N., Tsetlin V., Hucho F. Intracellular domain of nicotinic acetylcholine receptor: the importance of being unfolded // J. Neurochem. 2006. Vol. 97. Suppl. 1. P 63-67.

Kumar P., Meizel S. Nicotinic acetylcholine receptor subunits and associated proteins in human sperm // J. Biol. Chem. 2005. Vol. 280. P. 25928-25935.

Lindrstom J. Nicotinic acetylcholine receptors of muscles and nerves. Comparison of their structures, functional roles, and vulnerability to pathology // Ann. NY Acad. Sci. 2003. Vol. 993. P 41-52.

Lyukmanova E.N., Shenkarev M.A., Mineev S.N. et al. NMR structure and action on nicotinic acetylcholine receptors of water-soluble domain of human Lynx 1 // J. Biol. Chem. 2011. Vol. 286. P 10618-10627.

MacDermottA.B., Role L.W., Siegelbaum S.A. Presynaptic ionotropic receptors and the control of transmitter release // Annu. Rev. Neurosci. 1999. Vol. 22. P 443-485.

Miwa J.M., Ibanez-Tallon I., Crabtree G.W et al. lynx1, an endogenous toxin-like modulator of nicotinic acetylcholine receptors in the mammalian CNS // Neuron.

Miwa J.M., Stevens T.R., King S.L. et al. The prototoxin lynx1 acts on nicotinic acetylcholine receptors to balance neuronal activity and survival in vivo // Neuron. 2006. Vol. 51. P. 587-600.

Morishita H., Miwa J.M., Heintz N., Hensch T.K. Lynx1, a cholinergic brake, limits plasticity in adult visual cortex // Science. 2010. Vol. 330. P. 1238-1240.

Munoz P., Huenchuguala S., Paris I., Cuevas C. et al. Protective effects of nicotine against aminochrome- induced toxicity in substantia nigra derived cells: implications for Parkinson’s disease // Neurotox Res. 2012. Vol. 22. P. 177-80.

Osipov A.V., Kasheverov I.E., Makarova Y.V et al. Naturally occurring disulfide-bound dimers of threefingered toxins: a paradigm for biological activity diversification // J. Biol. Chem. 2008. Vol. 283. P. 4571-4580.

Osipov A.V., Rucktooa P., Kasheverov I.E. et al. Dimeric a-cobratoxin X-ray structure: localization of intermolecular disulfides and possible mode of binding to nicotinic acetylcholine receptors // J. Biol. Chem. 2012. Vol. 287. P. 6725-6734.

OzM., Lorke D.E., Yang K.H., Petroianu G. On the interaction of P-amyloid peptides and a7-nicotinic acetylcholine receptors in Alzheimer's disease // Curr. Alzheimer Res. 2013. Vol. 10. P. 618-30.

QuikM. Smoking, nicotine and Parkinson’s disease // Trends Neurosci. 2004. Vol. 27. P. 561-568.

QuikM., Burdia T., O’LearyK. Nicotinic receptors as CNS targets for Parkinson’s disease // Biochem. Pharmacol. 2007. Vol. 74. P. 1224-1234.

Parri H.R., Hernandez C.M., Dineley K.T. Research update: Alpha7 nicotinic acetylcholine receptor mechanisms in Alzheimer’s disease // Biochem. Pharmacol. Review. 2011. Vol. 82. P. 931-942.

Radcliffe PM., Sterling C.R., Tank A.W. Induction of tyrosine hydroxylase mRNA by nicotine in rat midbrain is inhibited by mifepristone // J. Neurochem. 2009. Vol. 109. P. 1272-1284.

Reitz A.B., Demeter D.A., Lee D.H.S. et al. Method for treating neurodegenerative disoders.

Ripoll N., BronnecM., Bourin M. Nicotinic receptors and schizophrenia // Curr. Med. Res. Opin. 2004. Vol. 20. P. 1057-1074.

Salvaterra P.M., MahlerH.R. Nicotinic acetylcholine receptor from rat brain. Solubilization, partial purification, and characterization // J. Biol. Chem. 1976. Vol. 251. P. 6327-6334.

Sciamanna M.A., Griesmann G.E., Williams C.L., Lennon VA. Nicotinic acetylcholine receptors of muscle and neuronal (alpha7) types coexpressed in a small cell lung carcinoma // J. Neurochem. 1997. Vol. 69. № 6. P. 2302-2311.

Serova L., Sabban E.L. Involvement of alpha 7 nicotinic acetylcholine receptors in gene expression of dopamine biosynthetic enzymes in rat brain // J. Pharmacol. Exp. Ther. 2002. Vol. 303. № 3. P. 896-903.

Smit A.B., Syed N.I., Schaap D. et al. A glia-derived acetylcholine-binding protein that modulates synaptic transmission // Nature. 2001. Vol. 411. P. 261-268.

Steinlein O.K. Nicotinic receptor mutations in human epilepsy // Prog. Brain Res. 2004. Vol. 145. P. 275-285.

Suzuki S., Kawamata J., Matsushita T. et al. 3-[(2,4-Dimethoxy)benzylidene]-anabaseine dihydrochloride protects against 6-hydroxy dopamine-induced parkinsonian neurodegeneration through a7 nicotinic acetylcholine receptor stimulation in rats // J. Neurosci. Res. 2013. Vol. 91. P. 462-471.

Taly A., Corringer P.J., Guedin D., Lestage P., Changeux J.P. Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system // Nat. Rev. Drug Discov. 2009. Vol. 8. P. 733-750.

Terlau H., Olivera B.M. Conus venoms: a rich source of novel ion channel-targeted peptides // Physiol. Rev. 2004. Vol. 84. P. 41-68.

Thacker E.L., O’Reilly E.J., WeisskopfM.G. et al. Temporal relationship between cigarette smoking and risk of Parkinson disease // Neurology. 2007. Vol. 68. P. 764-768.

Timofeeva O.A., Levin E.D. Glutamate and nicotinic receptor interactions in working memory: importance for the cognitive impairment of schizophrenia // Neuroscience.

Tsetlin V.I. Snake venom alpha-neurotoxins and other three-finger proteins // Eur. J. Biochem. 1999. Vol. 264. P. 281-286.

Tsetlin V., Hucho F. Nicotinic acetylcholine receptors at atomic resolution // Curr. Opin. Pharmacol. 2009. Vol. 9. P. 306-310.

Tsetlin V, Utkin Y., Kasheverov I. Polypeptide and peptide toxins, magnifying lenses for binding sites in nicotinic acetylcholine receptors // Biochem. Pharmacol. 2009. Vol. 78. P. 720-731.

Turner J.R., Castellano L.M., Blendy J.A. Nicotinic partial agonists varenicline and sazetidine-A have differential effects on affective behavior. //J. Pharmacol. Exp. Ther. 2010. Vol. 334. P. 665-72.

Unwin N. Refined structure of the nicotinic acetylcholine receptor at 4A resolution // J. Mol. Biol. 2005. Vol. 346. № 4. P 967-989.

Vincent A., Beeson D., Lang B. Molecular targets for autoimmune and genetic disorders of neuromuscular transmission // Eur. J. Biochem. 2000. Vol. 267. № 23. P. 6717-6728.

Wang H.Y., Lee D.H., D’Andrea M.R., Peterson P.A., ShankR.P., Reitz A.B. beta-Amyloid (1-42) binds to alpha7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer’s disease pathology // J. Biol. Chem. 2000. Vol. 275. P. 5626-5632.

Weltzin M.M., Schulte M.K. Pharmacological characterization of the allosteric modulator desformylflustra- bromine and its interaction with alpha4beta2 neuronal nicotinic acetylcholine receptor orthosteric ligands // J. Pharmacol. Exp. Ther. 2010. Vol. 334. P. 917-926.